Moxifloxacin

• CAT Number: I001877
• CAS Number: 151096-09-2
• Molecular Formula: C21H24FN3O4
• Molecular Weight: 401.43
• Purity: ≥95%
• Synonyms: 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
• Target: Bacterial
• Solubility: 10 mM in DMSO
• Storage: Store at -20C
• InChI: InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
• InChIKey: FABPRXSRWADJSP-MEDUHNTESA-N
• SMILES: COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O

Moxifloxacin（Cat No.:I001877）is a broad-spectrum fluoroquinolone antibiotic widely used to treat bacterial infections, including respiratory, skin, and intra-abdominal infections. It inhibits bacterial DNA gyrase and topoisomerase IV, enzymes critical for DNA replication, transcription, and repair, effectively halting bacterial growth. Known for its strong activity against both gram-positive and gram-negative bacteria, as well as some atypical pathogens, moxifloxacin is particularly effective for treating respiratory tract infections like pneumonia and bronchitis. Its oral and intravenous formulations offer flexible dosing options, making it a valuable antibiotic in both outpatient and hospital settings.

Reference

[1]. Balfour, J.A. and H.M. Lamb, Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs, 2000. 59(1): p. 115-39.

[2]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88.

[3]. Ioannidis, O., et al., Effect of moxifloxacin on the survival, lipid peroxidation and inflammation of immunosuppressed rats with soft tissue infection from Stenotrophomonas maltophilia. Microbiol Immunol, 2013.